Maze Therapeutics (MAZE) Cash from Financing Activities (2024 - 2026)
Maze Therapeutics (MAZE) posted Cash from Financing Activities of $42.4 million for Q1 2026, up 1079.86% sequentially from $3.6 million in Q4 2025, and down 66.75% YoY from $127.4 million in Q1 2025.
Maze Therapeutics (MAZE) Cash from Financing Activities (2024 - 2026) Analysis & Trends
Maze Therapeutics has reported Cash from Financing Activities for 3 years, with the latest figure at $42.4 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 66.75% year-over-year to $42.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.3 million (down 2.72% YoY) and the FY2025 annual result came in at $275.3 million, up 196.55% from the prior year.
- Cash from Financing Activities advanced to $42.4 million in Q1 2026 per MAZE's latest filing, from $3.6 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $143.8 million in Q3 2025 and troughed at -$2.2 million in Q3 2024.
- A 3-year average of $45.6 million and a median of $24.6 million in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 6786.37% in 2025, down 94.89% in 2025.
- Over 3 years, Cash from Financing Activities stood at $70.3 million in 2024, then plunged by 94.89% to $3.6 million in 2025, then jumped by 1079.86% to $42.4 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $42.4 million, $3.6 million, and $143.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Maze Therapeutics | 1.51 Bn | 1.51 Bn | - | 147.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 147.44 Mn |
| Jun 30, 2026 | 147.44 Mn |
| Mar 31, 2026 | 42.36 Mn |
| Mar 31, 2026 | 42.36 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Sep 30, 2025 | 143.76 Mn |
| Sep 30, 2025 | 143.76 Mn |
| Jun 30, 2025 | 612,000.00 |
| Jun 30, 2025 | 612,000.00 |
| Mar 31, 2025 | 127.38 Mn |
| Mar 31, 2025 | 127.38 Mn |
| Dec 31, 2024 | 70.26 Mn |
| Dec 31, 2024 | 70.26 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Sep 30, 2024 | -2.15 Mn |
| Jun 30, 2024 | 154,000.00 |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | 24.58 Mn |
| Mar 31, 2024 | 24.58 Mn |